Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Pieris Pharmaceuticals Inc (PIRS) USD0.001

Sell:$3.21 Buy:$3.22 Change: No change
NASDAQ:1.24%
Market closed |  Prices as at close on 15 October 2019 | Switch to live prices |
Sell:$3.21
Buy:$3.22
Change: No change
Market closed |  Prices as at close on 15 October 2019 | Switch to live prices |
Sell:$3.21
Buy:$3.22
Change: No change
Market closed |  Prices as at close on 15 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Contact details

Address:
255 State St Fl 9
BOSTON
02109-2615
United States
Telephone:
+1 (857) 2468998
Website:
https://www.pieris.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PIRS
ISIN:
US7207951036
Market cap:
$158.55 million
Shares in issue:
49.39 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Geraghty
    Chairman of the Board
  • Stephen Yoder
    President, Chief Executive Officer, Director
  • Thomas Bures
    Chief Financial Officer, Principal Accounting Officer, Treasurer
  • Hitto Kaufmann
    Senior Vice President, Chief Scientific Officer
  • Claude Knopf
    Senior Vice President, Chief Business Officer
  • Louis Matis
    Senior Vice President and Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.